Pfeilschifter J, Leighton J, Pignat W, Märki F, Vosbeck K
Research Department, Pharmaceuticals Division, Ciba-Geigy Ltd., Basel, Switzerland.
Biochem J. 1991 Jan 1;273(Pt 1)(Pt 1):199-204. doi: 10.1042/bj2730199.
We have previously shown that recombinant interleukin 1 (IL-1) and recombinant tumour necrosis factor (TNF) synergistically stimulate phospholipase A2 release from mesangial cells. We now report that treatment of mesangial cells with the beta-agonist salbutamol, prostaglandin E2 (PGE2), cholera toxin or forskolin, which all activate adenylate cyclase, increased release of phospholipase A2 activity. Likewise, addition of a membrane-permeant cyclic AMP (cAMP) analogue or the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine enhanced release of phospholipase A2 activity from mesangial cells. There was a lag period of about 8 h before a significantly enhanced secretion could be detected. Furthermore, actinomycin D or cycloheximide completely suppressed cAMP-stimulated secretion of phospholipase A2. Angiotensin II, the phorbol ester phorbol 12-myristate 13-acetate, the Ca2+ ionophore A23187 and a membrane-permeant cGMP analogue did not stimulate phospholipase A2 release from the cells. Treatment with indomethacin completely inhibited IL-1 beta- and TNF-stimulated PGE2 synthesis, without having any effect on phospholipase A2 secretion, thus excluding cytokine-induced PGE2 synthesis as the mediator of phospholipase A2 release. Neither IL-1 beta nor TNF induced any increase in intracellular cAMP in mesangial cells. Furthermore, incubation of the cells with 2',5'-dideoxyadenosine, an inhibitor of adenylate cyclase, did not block cytokine-stimulated phospholipase A2 secretion. In addition, IL-1 beta and TNF synergistically interacted with forskolin to stimulate phospholipase A2 release from the cells. The protein kinase inhibitors H-8, staurosporine, K252a and amiloride inhibited IL-1 beta- and TNF-stimulated phospholipase A2 secretion. However, high concentrations that inhibit other protein kinases were needed. These observations suggest that IL-1 beta and TNF cause secretion of phospholipase A2 by a mechanism independent of cAMP. The signalling pathways used by IL-1 beta and TNF may involve a protein kinase that is probably different from protein kinase A or protein kinase C.
我们之前已表明,重组白细胞介素1(IL-1)和重组肿瘤坏死因子(TNF)可协同刺激系膜细胞释放磷脂酶A2。我们现在报告,用β-激动剂沙丁胺醇、前列腺素E2(PGE2)、霍乱毒素或福斯可林处理系膜细胞,这些物质均可激活腺苷酸环化酶,从而增加磷脂酶A2活性的释放。同样,添加可透过细胞膜的环磷酸腺苷(cAMP)类似物或磷酸二酯酶抑制剂3-异丁基-1-甲基黄嘌呤可增强系膜细胞中磷脂酶A2活性的释放。在可检测到显著增强的分泌之前有大约8小时的延迟期。此外,放线菌素D或环己酰亚胺完全抑制了cAMP刺激的磷脂酶A2分泌。血管紧张素II、佛波酯佛波醇12-肉豆蔻酸酯13-乙酸酯、Ca2+离子载体A23187和可透过细胞膜的cGMP类似物均未刺激细胞释放磷脂酶A2。用吲哚美辛处理可完全抑制IL-1β和TNF刺激的PGE2合成,但对磷脂酶A2分泌没有任何影响,因此排除了细胞因子诱导的PGE2合成作为磷脂酶A2释放的介质。IL-1β和TNF均未诱导系膜细胞内cAMP增加。此外,用腺苷酸环化酶抑制剂2',5'-二脱氧腺苷孵育细胞并未阻断细胞因子刺激的磷脂酶A2分泌。此外,IL-1β和TNF与福斯可林协同相互作用以刺激细胞释放磷脂酶A2。蛋白激酶抑制剂H-8、星形孢菌素、K252a和阿米洛利抑制IL-1β和TNF刺激的磷脂酶A2分泌。然而,需要抑制其他蛋白激酶的高浓度抑制剂。这些观察结果表明,IL-1β和TNF通过一种独立于cAMP的机制导致磷脂酶A2分泌。IL-1β和TNF使用的信号通路可能涉及一种可能不同于蛋白激酶A或蛋白激酶C的蛋白激酶。